Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Rhea-AI Summary

Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotech company, has scheduled its first quarter 2025 financial results announcement and business update for May 8, 2025 after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day. Investors can access the conference call via 1.877.407.0789 with Conference ID 13752361. An archived replay will be available on the company's website following the event.

MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.

Conference Call and Webcast Details:
Conference Call Number:			1.877.407.0789
Conference ID:			13752361
Call meTM Feature:			Click Here
Webcast:			Click Here

An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

FAQ

When will Longeveron (LGVN) report Q1 2025 earnings?

Longeveron will report its Q1 2025 financial results on Thursday, May 8, 2025, after U.S. financial markets close.

What time is Longeveron's Q1 2025 earnings call?

Longeveron's Q1 2025 earnings conference call and webcast is scheduled for May 8, 2025 at 4:30 p.m. ET.

How can I access Longeveron's Q1 2025 earnings call?

Investors can access the conference call by dialing 1.877.407.0789 with Conference ID 13752361. A webcast will also be available.

What does Longeveron (LGVN) do as a company?

Longeveron is a clinical stage regenerative medicine biotechnology company that develops cellular therapies for life-threatening and chronic aging-related conditions.